Please note the ANZCTR will be unattended from 21/12/2018 until 08/01/2019. During this time no submissions or updates will be processed. Please ensure all trials are submitted/updated as soon as possible if you wish for them to be reviewed prior to the unattended period.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00087711




Registration number
NCT00087711
Ethics application status
Date submitted
12/07/2004
Date registered
15/07/2004
Date last updated
21/11/2016

Titles & IDs
Public title
A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
Scientific title
A Randomized Phase 3 Trial of ALIMTA and Cisplatin Versus GEMZAR and Cisplatin in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Secondary ID [1] 0 0
H3E-MC-JMDB
Secondary ID [2] 0 0
2938
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non Small Cell Lung Carcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - pemetrexed
Treatment: Drugs - gemcitabine
Treatment: Drugs - cisplatin

Experimental: A -

Active Comparator: B -


Treatment: Drugs: pemetrexed
500 mg/m2, IV q 21 days x 6 cycles

Treatment: Drugs: gemcitabine
1250 mg/m2, IV, day 1 and 8 q 21 days x 6 cycles

Treatment: Drugs: cisplatin
75 mg/m2, IV, q 21 days x 6 cycles

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall survival
Timepoint [1] 0 0
baseline to date of death from any cause
Secondary outcome [1] 0 0
Progression free survival
Timepoint [1] 0 0
baseline to measured progressive disease
Secondary outcome [2] 0 0
Time to progressive disease
Timepoint [2] 0 0
baseline to measured progressive disease
Secondary outcome [3] 0 0
Duration of response
Timepoint [3] 0 0
time of response to progressive disease
Secondary outcome [4] 0 0
Time to treatment failure
Timepoint [4] 0 0
baseline to stopping treatment

Eligibility
Key inclusion criteria
- Diagnosis of NSCLC Stage IIIB not amenable to curative treatment or Stage IV.

- No prior chemotherapy for lung cancer.

- Patients must have at least one uni-dimensionally measurable lesion.

- Prior radiation therapy to less than 25% of bone marrow, whole pelvis not allowed.
Radiation must be completed at least 4 weeks prior to study enrollment.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Treatment with any drug within the last 30 days that has not received regulatory
approval.

- Serious cardiac condition.

- Serious medical disorder in addition to NSCLC that would make it difficult for the
patient to complete the study.

- Inability or unwillingness to take folic acid or Vitamin B12 supplementation.

- Presence of fluid retention that cannot be controlled by drainage.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Bedford Park
Recruitment hospital [2] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Camperdown
Recruitment hospital [3] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Chermisdie
Recruitment hospital [4] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Fitzroy
Recruitment hospital [5] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Hornsby
Recruitment hospital [6] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Nedlands
Recruitment hospital [7] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - South Brisbane
Recruitment hospital [8] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - St Leonards
Recruitment postcode(s) [1] 0 0
- Bedford Park
Recruitment postcode(s) [2] 0 0
- Camperdown
Recruitment postcode(s) [3] 0 0
- Chermisdie
Recruitment postcode(s) [4] 0 0
- Fitzroy
Recruitment postcode(s) [5] 0 0
- Hornsby
Recruitment postcode(s) [6] 0 0
- Nedlands
Recruitment postcode(s) [7] 0 0
- South Brisbane
Recruitment postcode(s) [8] 0 0
- St Leonards
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Kansas
Country [5] 0 0
United States of America
State/province [5] 0 0
Kentucky
Country [6] 0 0
United States of America
State/province [6] 0 0
Maine
Country [7] 0 0
United States of America
State/province [7] 0 0
Minnesota
Country [8] 0 0
United States of America
State/province [8] 0 0
Missouri
Country [9] 0 0
United States of America
State/province [9] 0 0
Montana
Country [10] 0 0
United States of America
State/province [10] 0 0
New Jersey
Country [11] 0 0
United States of America
State/province [11] 0 0
North Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Oregon
Country [13] 0 0
United States of America
State/province [13] 0 0
South Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Tennessee
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
United States of America
State/province [16] 0 0
Virginia
Country [17] 0 0
United States of America
State/province [17] 0 0
Washington
Country [18] 0 0
Argentina
State/province [18] 0 0
Bahia Blanca
Country [19] 0 0
Argentina
State/province [19] 0 0
Buenos Aires
Country [20] 0 0
Austria
State/province [20] 0 0
Graz
Country [21] 0 0
Austria
State/province [21] 0 0
Grimmenstein
Country [22] 0 0
Austria
State/province [22] 0 0
Innsbruck
Country [23] 0 0
Austria
State/province [23] 0 0
Leoben
Country [24] 0 0
Austria
State/province [24] 0 0
Linz
Country [25] 0 0
Austria
State/province [25] 0 0
St. Poelten
Country [26] 0 0
Austria
State/province [26] 0 0
Vienna
Country [27] 0 0
Austria
State/province [27] 0 0
Wels
Country [28] 0 0
Belgium
State/province [28] 0 0
Leuven
Country [29] 0 0
Belgium
State/province [29] 0 0
Liege
Country [30] 0 0
Brazil
State/province [30] 0 0
Florianopolis
Country [31] 0 0
Brazil
State/province [31] 0 0
Porto Alegre
Country [32] 0 0
Brazil
State/province [32] 0 0
Rio De Janeiro
Country [33] 0 0
Brazil
State/province [33] 0 0
Salvador
Country [34] 0 0
Brazil
State/province [34] 0 0
Sao Paulo
Country [35] 0 0
Canada
State/province [35] 0 0
British Columbia
Country [36] 0 0
Canada
State/province [36] 0 0
Ontario
Country [37] 0 0
Canada
State/province [37] 0 0
Quebec
Country [38] 0 0
Denmark
State/province [38] 0 0
Herlev
Country [39] 0 0
Denmark
State/province [39] 0 0
Odense
Country [40] 0 0
Finland
State/province [40] 0 0
Helsinki
Country [41] 0 0
Finland
State/province [41] 0 0
Tampere
Country [42] 0 0
France
State/province [42] 0 0
Bordeaux
Country [43] 0 0
France
State/province [43] 0 0
Grenoble
Country [44] 0 0
France
State/province [44] 0 0
Marseille
Country [45] 0 0
France
State/province [45] 0 0
Montpellier
Country [46] 0 0
France
State/province [46] 0 0
Paris
Country [47] 0 0
France
State/province [47] 0 0
Saint Herblain
Country [48] 0 0
France
State/province [48] 0 0
Strasbourg
Country [49] 0 0
France
State/province [49] 0 0
Vandoeuvre-les-Nancy
Country [50] 0 0
Germany
State/province [50] 0 0
Mannheim
Country [51] 0 0
Greece
State/province [51] 0 0
Athens
Country [52] 0 0
Greece
State/province [52] 0 0
Heraklion
Country [53] 0 0
Greece
State/province [53] 0 0
Patras
Country [54] 0 0
Hungary
State/province [54] 0 0
Budapest
Country [55] 0 0
Hungary
State/province [55] 0 0
Deszk
Country [56] 0 0
Hungary
State/province [56] 0 0
Pecs
Country [57] 0 0
India
State/province [57] 0 0
Bangalore
Country [58] 0 0
India
State/province [58] 0 0
Cochin
Country [59] 0 0
India
State/province [59] 0 0
Hyderabad
Country [60] 0 0
India
State/province [60] 0 0
Mumbai
Country [61] 0 0
India
State/province [61] 0 0
New Dehli
Country [62] 0 0
India
State/province [62] 0 0
Pune
Country [63] 0 0
Israel
State/province [63] 0 0
Kfar Saba
Country [64] 0 0
Israel
State/province [64] 0 0
Tel-Aviv
Country [65] 0 0
Israel
State/province [65] 0 0
Tel-Hashomer
Country [66] 0 0
Italy
State/province [66] 0 0
Ancona
Country [67] 0 0
Italy
State/province [67] 0 0
Bergamo
Country [68] 0 0
Italy
State/province [68] 0 0
Bologna
Country [69] 0 0
Italy
State/province [69] 0 0
Forli
Country [70] 0 0
Italy
State/province [70] 0 0
Genova
Country [71] 0 0
Italy
State/province [71] 0 0
Livorno
Country [72] 0 0
Italy
State/province [72] 0 0
Modena
Country [73] 0 0
Italy
State/province [73] 0 0
Orbassano
Country [74] 0 0
Italy
State/province [74] 0 0
Roma
Country [75] 0 0
Italy
State/province [75] 0 0
Taormina
Country [76] 0 0
Korea, Republic of
State/province [76] 0 0
Goyang-Si
Country [77] 0 0
Korea, Republic of
State/province [77] 0 0
Seoul
Country [78] 0 0
Mexico
State/province [78] 0 0
Ciudad Obregon
Country [79] 0 0
Mexico
State/province [79] 0 0
Guadalajara
Country [80] 0 0
Mexico
State/province [80] 0 0
Leon
Country [81] 0 0
Mexico
State/province [81] 0 0
Mexicali
Country [82] 0 0
Mexico
State/province [82] 0 0
Mexico City
Country [83] 0 0
Netherlands
State/province [83] 0 0
Alkmaar
Country [84] 0 0
Netherlands
State/province [84] 0 0
Amstelveen
Country [85] 0 0
Netherlands
State/province [85] 0 0
Amsterdam
Country [86] 0 0
Netherlands
State/province [86] 0 0
Arnhem
Country [87] 0 0
Netherlands
State/province [87] 0 0
Den Bosch
Country [88] 0 0
Netherlands
State/province [88] 0 0
Eindhoven
Country [89] 0 0
Netherlands
State/province [89] 0 0
Harderwijk
Country [90] 0 0
Netherlands
State/province [90] 0 0
Heerlen
Country [91] 0 0
Poland
State/province [91] 0 0
Krakow
Country [92] 0 0
Poland
State/province [92] 0 0
Lodz
Country [93] 0 0
Poland
State/province [93] 0 0
Szczecin-Zdunowo
Country [94] 0 0
Poland
State/province [94] 0 0
Warszawa
Country [95] 0 0
Portugal
State/province [95] 0 0
Coimbra
Country [96] 0 0
Portugal
State/province [96] 0 0
Lisboa
Country [97] 0 0
Portugal
State/province [97] 0 0
Porto
Country [98] 0 0
Portugal
State/province [98] 0 0
Santa Maria Da Feira
Country [99] 0 0
Puerto Rico
State/province [99] 0 0
San Juan
Country [100] 0 0
Spain
State/province [100] 0 0
Alicante
Country [101] 0 0
Spain
State/province [101] 0 0
Badalona
Country [102] 0 0
Spain
State/province [102] 0 0
Barcelona
Country [103] 0 0
Spain
State/province [103] 0 0
Madrid
Country [104] 0 0
Spain
State/province [104] 0 0
Pamplona
Country [105] 0 0
Spain
State/province [105] 0 0
Sabadell
Country [106] 0 0
Spain
State/province [106] 0 0
Santander
Country [107] 0 0
Spain
State/province [107] 0 0
Zaragoza
Country [108] 0 0
Sweden
State/province [108] 0 0
Goteborg
Country [109] 0 0
Sweden
State/province [109] 0 0
Lund
Country [110] 0 0
Sweden
State/province [110] 0 0
Stockholm
Country [111] 0 0
Taiwan
State/province [111] 0 0
Niao Sung Hsiang
Country [112] 0 0
Taiwan
State/province [112] 0 0
Taichung
Country [113] 0 0
Taiwan
State/province [113] 0 0
Taipei
Country [114] 0 0
Taiwan
State/province [114] 0 0
Tao-Yuan
Country [115] 0 0
Turkey
State/province [115] 0 0
Ankara
Country [116] 0 0
Turkey
State/province [116] 0 0
Antalya
Country [117] 0 0
Turkey
State/province [117] 0 0
Istanbul
Country [118] 0 0
Turkey
State/province [118] 0 0
Izmir
Country [119] 0 0
United Kingdom
State/province [119] 0 0
Aberdeen
Country [120] 0 0
United Kingdom
State/province [120] 0 0
Bangor
Country [121] 0 0
United Kingdom
State/province [121] 0 0
Chelmsford
Country [122] 0 0
United Kingdom
State/province [122] 0 0
Fulham
Country [123] 0 0
United Kingdom
State/province [123] 0 0
Plymouth
Country [124] 0 0
United Kingdom
State/province [124] 0 0
Sutton

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Eli Lilly and Company
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study is a randomized Phase 3 study comparing pemetrexed and cisplatin combination to
gemcitabine and cisplatin for the treatment of Non Small Cell Lung Cancer (NCSLC).
Gemcitabine plus cisplatin is currently the standard of care for NSCLC. It is thought that
pemetrexed plus cisplatin may be as effective and may have fewer side effects than the
standard of care.
Trial website
https://clinicaltrials.gov/show/NCT00087711
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No data has been provided for results reporting
Summary results
Other publications